GH Research PLC (NASDAQ:GHRS – Free Report) – Equities research analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of GH Research in a research note issued on Monday, August 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.14) per share for the year, up from their previous forecast of ($1.21). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for GH Research’s current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for GH Research’s Q4 2026 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.46) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($2.11) EPS and FY2030 earnings at ($1.22) EPS.
GH Research (NASDAQ:GHRS – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.06.
Read Our Latest Research Report on GH Research
GH Research Trading Down 1.5%
GH Research stock opened at $29.08 on Wednesday. The firm has a market capitalization of $2.00 billion, a P/E ratio of -29.08 and a beta of 1.29. GH Research has a twelve month low of $11.80 and a twelve month high of $31.44. The stock’s fifty day simple moving average is $25.88 and its 200-day simple moving average is $20.37.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC raised its position in shares of GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after acquiring an additional 822 shares in the last quarter. North Star Investment Management Corp. acquired a new position in GH Research in the first quarter valued at approximately $31,000. Royal Bank of Canada boosted its holdings in GH Research by 43.1% in the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after purchasing an additional 780 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in GH Research in the fourth quarter valued at approximately $38,000. Finally, Osaic Holdings Inc. increased its stake in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.
GH Research News Roundup
Here are the key news stories impacting GH Research this week:
- Positive Sentiment: HC Wainwright maintained its Buy rating and raised its FY2026 EPS forecast to a loss of $1.14 from a loss of $1.21. The firm also improved its FY2027 estimate to a loss of $1.62 from $1.64, indicating expectations for somewhat lower losses than previously projected.
- Positive Sentiment: The analyst raised quarterly EPS forecasts for Q4 2026, Q2 2027, Q3 2027 and Q4 2027 by $0.01 each, to losses of $0.31, $0.38, $0.42 and $0.46, respectively. These revisions may support GHRS by signaling improved cost or development-spending expectations.
- Neutral Sentiment: HC Wainwright initiated longer-term estimates calling for losses of $1.76 per share in FY2028, $2.11 in FY2029 and $1.22 in FY2030. The forecasts provide a valuation framework but do not imply near-term profitability.
- Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from July 27, with a zero-day days-to-cover ratio. The data offers no indication of meaningful short-selling pressure or potential short-covering demand, though the reported figures appear unusual.
- Negative Sentiment: GH Research is still expected to post a current-year loss of approximately $1.33 per share, and all of HC Wainwright’s published forecasts through FY2030 remain negative. Investors therefore continue to depend on clinical and commercial progress rather than current earnings.
About GH Research
GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.
The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.
Featured Articles
- Five stocks we like better than GH Research
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
